1663 related articles for article (PubMed ID: 12732390)
1. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
[TBL] [Abstract][Full Text] [Related]
2. Which fasting triglyceride levels best reflect coronary risk? Evidence from the Turkish Adult Risk Factor Study.
Onat A; Sansoy V; Yildirim B
Clin Cardiol; 2001 Jan; 24(1):9-14. PubMed ID: 11195622
[TBL] [Abstract][Full Text] [Related]
3. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks.
Onat A; Hergenç G; Ayhan E; Uğur M; Kaya H; Tuncer M; Can G
Diabet Med; 2009 Oct; 26(10):981-8. PubMed ID: 19900229
[TBL] [Abstract][Full Text] [Related]
4. [Lipoprotein (a) in a population-based study: more significant in Turkish women than men?].
Onat A; Yazici M; Hergenç G; Doğan Y; Karabulut A; Sari I; Türkmen S; Can G; Sansoy V
Anadolu Kardiyol Derg; 2005 Dec; 5(4):271-7. PubMed ID: 16330391
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.
Onat A; Ceyhan K; Başar O; Erer B; Toprak S; Sansoy V
Atherosclerosis; 2002 Dec; 165(2):285-92. PubMed ID: 12417279
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
7. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.
Mendivil CO; Rimm EB; Furtado J; Chiuve SE; Sacks FM
Circulation; 2011 Nov; 124(19):2065-72. PubMed ID: 21986282
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein and coronary heart disease in western Turkey.
Onat A; Sansoy V; Yildirim B; Keleş I; Uysal O; Hergenç G
Am J Cardiol; 2001 Sep; 88(6):601-7. PubMed ID: 11564380
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
[TBL] [Abstract][Full Text] [Related]
10. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
[TBL] [Abstract][Full Text] [Related]
11. The hypertriglyceridemic waist phenotype among women.
LaMonte MJ; Ainsworth BE; DuBose KD; Grandjean PW; Davis PG; Yanowitz FG; Durstine JL
Atherosclerosis; 2003 Nov; 171(1):123-30. PubMed ID: 14642414
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.
Mendivil CO; Rimm EB; Furtado J; Sacks FM
J Am Heart Assoc; 2013 May; 2(3):e000130. PubMed ID: 23672999
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
[TBL] [Abstract][Full Text] [Related]
14. High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.
Jensen MK; Aroner SA; Mukamal KJ; Furtado JD; Post WS; Tsai MY; Tjønneland A; Polak JF; Rimm EB; Overvad K; McClelland RL; Sacks FM
Circulation; 2018 Mar; 137(13):1364-1373. PubMed ID: 29162611
[TBL] [Abstract][Full Text] [Related]
15. Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels.
Ruixing Y; Yiyang L; Meng L; Kela L; Xingjiang L; Lin Z; Wanying L; Jinzhen W; Dezhai Y; Weixiong L
Lipids Health Dis; 2010 Aug; 9():86. PubMed ID: 20716347
[TBL] [Abstract][Full Text] [Related]
16. Fasting insulin levels independently associated with coronary heart disease in non-diabetic Turkish men and women.
Onat A; Ceyhan K; Sansoy V; Basar O; Erer B; Uysal O; Hergenç G
Int J Cardiol; 2002 Nov; 86(1):61-9. PubMed ID: 12243850
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional study of complement C3 as a coronary risk factor among men and women.
Onat A; Uzunlar B; Hergenç G; Yazici M; Sari I; Uyarel H; Can G; Sansoy V
Clin Sci (Lond); 2005 Feb; 108(2):129-35. PubMed ID: 15487975
[TBL] [Abstract][Full Text] [Related]
19. Lipid assessment, metabolic syndrome and coronary heart disease risk.
Arsenault BJ; Després JP; Stroes ES; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
Eur J Clin Invest; 2010 Dec; 40(12):1081-93. PubMed ID: 20701625
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
